Biotechnology

The Readout LOUD

LISTEN: Gilead’s new boss, the year that was, and the thing about DNA tests

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Broken pills concept

Biotech

What to watch in biotech at the JPM Healthcare Conference and beyond in 2019

By Adam Feuerstein

advertisement

Worst Biotech CEOs 2017

Adam's Take

And now, your nominees for worst biopharma CEO of 2018. Let the voting begin!

By Adam Feuerstein

advertisement

Best Biotech CEOs 2017

Adam's Take

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

By Adam Feuerstein

Adam's Take

Why Gilead’s new CEO is a solid choice to help the biotech grow again

By Adam Feuerstein

Biotech

Moderna’s record-setting IPO dives in its debut

By Damian Garde

The Readout LOUD

LISTEN: Using the word ‘cure,’ an FDA loophole, & making biotech history

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

advertisement

AI neuron illustration

First Opinion

Artificial intelligence in pharma, health care: at the crossroads of hype and reality

By Grant Stephen and Michael Jacobson

advertisement

Donald Trump & Xi Jinping

Politics

The Trump administration called this biotech VC firm a suspicious agent of China. It’s run by U.S. citizens

By Rebecca Robbins

Steve Burrill

Biotech

Legendary biotech VC Steven Burrill sentenced to 2.5 years for fraud

By Damian Garde

Biotech

Four big questions ahead of Moderna’s public debut — biotech’s biggest ever

By Damian Garde

Foundation Medicine

Biotech

For one cancer patient, biotech’s genetic test turns out to be a ‘lifesaver’

By Jonathan Saltzman — Boston Globe

Biotech

Bluebird’s gene therapy improved outcomes for patients, as push for filing gains steam

By Adam Feuerstein

Gene Therapy Sickle Cell

Biotech

Global Blood, FDA agree on fast-filing plan for new sickle cell disease drug

By Adam Feuerstein

Ovarian Tumor

Biotech

GSK buys cancer biotech Tesaro for $5.1B

By Adam Feuerstein

Harbour Bio-Med

Biotech

Pharma Valley, China’s equivalent of Kendall Square, is expanding rapidly

By Yi-Ling Liu

The US Capitol

Politics

The new Congress is already threatening to push forward on drug pricing, but BIO CEO Jim Greenwood isn’t changing tack

By Nicholas Florko

Biotech

Unbowed by critics, Gilead’s cancer chief pushes ahead with growth plans

By Adam Feuerstein

Adam's Take

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

By Adam Feuerstein

Biotech

The benefit of a blood disease drug from Acceleron and Celgene debated by experts

By Adam Feuerstein

Dr. Erica Esrick and Manny Jones

Biotech

Novel gene therapy ‘switch’ for sickle cell disease shows encouraging results in pilot trial

By Adam Feuerstein

Biotech

The CRISPR’d twins controversy upended the world of science. Wall Street? Not so much

By Kate Sheridan

Biotech

FDA signs off on Editas CRISPR study on patients with a rare genetic disorder

By Damian Garde

MassNextGen

Biotech

Almost no venture capital funding goes to women. Can a pitchfest bring parity to biotech?

By Kate Sheridan

Biotech

With schizophrenia drug results, Alkermes gets much-needed good news. But insurers could pose challenge

By Adam Feuerstein

STAT SPOTLIGHT

Biotech

Startup Spotlight: Gates-backed biotech Vir starts its first clinical trial

By Kate Sheridan

Vertex

Biotech

Vertex cystic fibrosis drug combination shows strong results in pivotal clinical trials

By Adam Feuerstein

prostate cancer cells

Biotech

Loxo’s cancer drug wins a pioneering FDA approval. Now it has to find some patients

By Damian Garde

Adam's Take

Ziopharm shares are moving higher on a turnaround strategy, but is it for real? A closer look

By Adam Feuerstein